| Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral … PJ Hanley, CRY Cruz, B Savoldo, AM Leen, M Stanojevic, M Khalil, ... Blood, The Journal of the American Society of Hematology 114 (9), 1958-1967, 2009 | 289 | 2009 |
| SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein MD Keller, KM Harris, MA Jensen-Wachspress, VV Kankate, H Lang, ... Blood, The Journal of the American Society of Hematology 136 (25), 2905-2917, 2020 | 122 | 2020 |
| Immunotherapy of relapsed and refractory solid tumors with ex vivo expanded multi-tumor associated antigen specific cytotoxic T lymphocytes: a phase I study AB Hont, CR Cruz, R Ulrey, B O’Brien, M Stanojevic, A Datar, S Albihani, ... Journal of Clinical Oncology 37 (26), 2349, 2019 | 67 | 2019 |
| Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT H Kinoshita, KR Cooke, M Grant, M Stanojevic, CR Cruz, M Keller, ... Blood advances 6 (8), 2520-2534, 2022 | 26 | 2022 |
| The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease AB Hont, AB Powell, DK Sohai, IK Valdez, M Stanojevic, AE Geiger, ... Molecular Therapy 30 (6), 2130-2152, 2022 | 20 | 2022 |
| Tumor-associated antigen–specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma H Dave, M Terpilowski, M Mai, K Toner, M Grant, M Stanojevic, C Lazarski, ... Blood Advances 6 (2), 473-485, 2022 | 15 | 2022 |
| Complete remissions post infusion of multiple tumor antigen specific T cells for the treatment of high risk leukemia and lymphoma patients after HCT KM Williams, P Hanley, M Grant, MF Fortiz, M Stanojevic, M Ismail, F Hoq, ... Blood 130, 4516, 2017 | 13 | 2017 |
| Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies M Stanojevic, AB Hont, A Geiger, S O'Brien, R Ulrey, M Grant, A Datar, ... Cytotherapy 23 (8), 694-703, 2021 | 11 | 2021 |
| Advances in fetal surgery: current and future relevance in plastic surgery A Gimenez, R Kopkin, DK Chang, M Belfort, EM Reece Seminars in plastic surgery 33 (03), 204-212, 2019 | 9 | 2019 |
| Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains M Stanojevic, A Geiger, B Ostermeier, D Sohai, C Lazarski, H Lang, ... Cytotherapy 24 (1), 10-15, 2022 | 8 | 2022 |
| Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular … M Stanojevic, A Bertaina, C Bonfim, R Ciccocioppo, S Cohen, D Purtill, ... Cytotherapy 24 (9), 884-891, 2022 | 3 | 2022 |
| Ex vivo expanded multi-antigen specific lymphocytes for the treatment of solid tumors. A Houghtelin, CR Cruz, R Ulrey, B O'Brien, M Stanojevic, S Albihaini, ... Journal of Clinical Oncology 36 (15_suppl), 3042-3042, 2018 | 3 | 2018 |
| Complete tumor responses in lymphoma patients who receive autologous cytotoxic T lymphocytes targeting EBV latent membrane proteins CM Bollard, M Stanojevic, AM Leen, T Lopez, AN Sheehan, G Carrum, ... Blood, The Journal of the American Society of Hematology 112 (11), 230-230, 2008 | 3 | 2008 |
| Peripheral blood marker of residual acute leukemia after hematopoietic cell transplantation using multi-plex digital droplet PCR M Stanojevic, M Grant, SK Vesely, S Knoblach, CG Kanakry, J Nazarian, ... Frontiers in Immunology 13, 999298, 2022 | 2 | 2022 |
| others. Immunotherapy of relapsed and refractory solid tumors with ex vivo expanded multiantigen-associated specific cytotoxic T lymphocytes: A Phase I Study AB Hont, CR Cruz, R Ulrey, B O’Brien, M Stanojevic, A Datar, S Albihani, ... J Clin Oncol, 2019 | 2 | 2019 |
| Identification of Novel HLA-Restricted PRAME Peptides to Facilitate off-the-shelf Tumor-Associated Antigen-specific T-cell Therapies M Stanojevic, AB Hont, A Geiger, S O’Brien, R Ulrey, M Grant, A Datar, ... Cytotherapy 23 (8), 694, 2021 | 1 | 2021 |
| Coronavirus-specific T-cells can be rapidly expanded from convalescent donors for potential clinical use MD Keller, KM Harris, S Conway, J Durkee-Shock, M Jensen-Wachspress, ... Transplantation and Cellular Therapy 27 (3), S70, 2021 | 1 | 2021 |
| Tumor Associated Antigen Specific T Cells Given in Combination with Nivolumab for the Treatment of Hodgkin Lymphoma H Dave, M Mai, M Terpilowski, K Toner, M Stanojevic, M Galligan, A Shibli, ... Blood 136, 18, 2020 | 1 | 2020 |
| Simultaneous Detection of Circulating Tumor Antigens in Acute Leukemia after HSCT M Stanojevic, M Grant, J Nazarian, S Knoblach, E Panditharatna, ... Biology of Blood and Marrow Transplantation 26 (3), S123, 2020 | 1 | 2020 |
| Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for" off-the-shelf" treatment of cancer expressing prame CM Bollard, P Hanley, CRY Cruz, M Stanojevic, A Hont US Patent App. 17/926,188, 2023 | | 2023 |
